Author:
Kobayashi Miwako,Farrar Jennifer L.,Gierke Ryan,Leidner Andrew J.,Campos-Outcalt Doug,Morgan Rebecca L.,Long Sarah S.,Poehling Katherine A.,Cohen Adam L.,Poehling Katherine A.,Long Sarah S.,Kelman Jeffrey,Lee Lucia,Mongeau Tina,Weiser Thomas,Chukwuma Uzo,Lu Kristina,Makhene Mamodikoe,Fisher Lynn,Sawyer Mark,Goldman Jason,Nace David,Messerli Emily,Abrams Elissa,Wierzbowski Aleksandra,Baker Carol,McAuley James,Schaffner William,Cane Virginia,Campos-Outcalt Doug,Farley Monica M.,Klugman Keith,Morgan Rebecca L.,Reingold Arthur,Rubin Lorry,Whitney Cynthia,Zimmerman Richard K.,Accorsi Emma,Albert Alison,Bhatnagar Shriya,Childs Lana,Fischer Marc,Gorwitz Rachel,Jiles Angela,Moline Heidi,Moro Pedro,Nsofor Chukwuebuka,Prasad Namrata,Walker Heather,Risalvato Jacquline,Schillie Sarah, ,
Publisher
Centers for Disease Control MMWR Office
Subject
Health Information Management,Health, Toxicology and Mutagenesis,General Medicine,Health (social science),Epidemiology
Reference32 articles.
1. Prevention of pneumococcal disease among infants and children—use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP).;Nuorti;MMWR Recomm Rep,2010
2. Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among children aged 6–18 years with immunocompromising conditions: recommendations of the Advisory Committee on Immunization Practices (ACIP).;CDC;MMWR Morb Mortal Wkly Rep,2013
3. Food and Drug Administration. Approval letter: Vaxneuvance. Silver Spring, MD: US Department of Health and Human Services, Food and Drug Administration; 2021. https://www.fda.gov/media/150820/download
4. Food and Drug Administration. Approval letter: Vaxneuvance. Silver Spring, MD: US Department of Health and Human Services, Food and Drug Administration; 2022. https://www.fda.gov/media/159338/download
5. Farrar J, Nsofor C, Childs L, Kobayashi M, Pilishvili T. Systematic review of 13-valent pneumococcal conjugate vaccine effectiveness against pneumonia among children. 12th International Symposium on Pneumococci and Pneumococcal Diseases meeting presentation; Toronto, Canada; June 21, 2022.